Division of Anti-Aging and Longevity Sciences, Faculty of Clinical Engineering, Department of Medical Engineering, Toin University of Yokohama, 1614 Kurogane-cho, Aoba-ku, Yokohama, Kanagawa 225-8502, Japan.
Mod Rheumatol. 2010 Jun;20(3):238-43. doi: 10.1007/s10165-009-0261-2. Epub 2010 Feb 9.
We prospectively compared the anti-inflammatory and antidyslipidemic effects of fenofibrate and statins in rheumatoid arthritis (RA) patients. Forty-four RA patients [male (M) = 7, female (F) = 37] with dyslipidemia were enrolled in this 6-month study and randomly allocated to the fenofibrate (2 M + 21 F = 23) or statins (5 M + 16 F = 21) group. We measured blood chemistry (serum lipid profile, sugar, urate, and gamma-glutamyl transpeptidase) and blood pressure 2 h after breakfast. Visual analog scale (VAS), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and prednisolone (PSL) dosage were also recorded immediately before and after the study. Fenofibrate, but not statins, significantly decreased serum levels of total cholesterol, low-density lipoprotein-cholesterol, and triglycerides (all p < 0.05). A significant improvement in VAS was observed in both the fenofibrate group (49.1 +/- 24.7 --> 14.7 +/- 11.2; p < 0.0001) and the statins group (47.4 +/- 29.7 --> 20.2 +/- 16.5; p < 0.001). PSL dosage significantly decreased only in the fenofibrate group (3.58 +/- 2.68 --> 2.00 +/- 2.22 mg/day; p < 0.01). Significant correlation was observed between VAS and CRP in the fenofibrate group (p < 0.05). Fenofibrate showed more anti-inflammatory and antidyslipidemic activity than statins in RA.
我们前瞻性地比较了贝特类药物和他汀类药物在类风湿关节炎（RA）患者中的抗炎和抗脂作用。这项为期 6 个月的研究纳入了 44 名血脂异常的 RA 患者[男性（M）=7，女性（F）=37]，并随机分为贝特组（2M+21F=23）或他汀组（5M+16F=21）。我们测量了早餐后 2 小时的血液化学（血脂谱、血糖、尿酸和γ-谷氨酰转肽酶）和血压。在研究前后还记录了视觉模拟量表（VAS）、C 反应蛋白（CRP）、红细胞沉降率（ESR）和泼尼松龙（PSL）剂量。贝特类药物而非他汀类药物可显著降低总胆固醇、低密度脂蛋白胆固醇和甘油三酯水平（均 P<0.05）。贝特组（49.1+/-24.7→14.7+/-11.2；p<0.0001）和他汀组（47.4+/-29.7→20.2+/-16.5；p<0.001）的 VAS 均显著改善。仅在贝特组中 PSL 剂量显著降低（3.58+/-2.68→2.00+/-2.22mg/天；p<0.01）。贝特组 VAS 与 CRP 之间存在显著相关性（p<0.05）。贝特类药物在 RA 中具有比他汀类药物更强的抗炎和抗脂作用。
